ĀÜĄņĀŅĀ×

Kyle Carver has served as a chief financial officer since March 2022. Prior to Evommune, Kyle served in various positions at Kadmon Holdings, Inc., a Sanofi Company, most recently as chief accounting officer. In these roles, he oversaw all aspects of financial and accounting operations, including Kadmonā€™s transition to a public company in its 2016 initial public offering through the approval and commercialization of REZUROCKā„¢ (belumosudil) in 2021. Mr. Carver drove significant improvement in accounting operations and internal controls, helped raised over $500 million through follow-on and convertible note offerings, and contributed to deal-making activities, including the acquisition of Kadmon by Sanofi for $1.9 billion in November 2021. Prior to Kadmon, Mr. Carver held a senior role at KPMG, serving a broad base of life science clients. Mr. Carver earned an MBA from the Stern School of Business at New York University and a BS in accounting from Villanova University. He is a certified public accountant.